Catalog No.
DHC90709
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a-lambda
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
2.14 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAS: 208921-02-2
Clone ID
Tositumomab
Tositumomab, PMID: 31643663
I-131 tositumomab, PMID: 20590521
Tositumomab I 131, PMID: 29999771
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma, PMID: 15653661
131 I-Tositumomab, PMID: 20641455
Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma, PMID: 14748653
131I tositumomab, PMID: 18034570
A clinical and scientific overview of tositumomab and iodine I 131 tositumomab, PMID: 12728404
Tositumomab and iodine I 131 tositumomab (Bexaar), PMID: 21436340
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab, PMID: 12728405
Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma, PMID: 17547519
A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma, PMID: 15934835
Targeted Radionuclide Therapy: A Historical and Personal Review, PMID: 31843064
Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view, PMID: 15640794
Iodine-131 tositumomab (Bexxar) in a radiation oncology environment, PMID: 16979436
Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab, PMID: 21386787
I-Tositumomab in lymphoma, PMID: 19862360
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies, PMID: 28918995
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma, PMID: 27798787
Development of 131I-tositumomab, PMID: 15786026
131I-tositumomab therapy as initial treatment for follicular lymphoma, PMID: 15689582
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications, PMID: 15547634
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab, PMID: 17530015
Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members, PMID: 11779293
Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab, PMID: 12899647
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19, PMID: 33131530
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice, PMID: 17942813
Observational Retrospective Study of Altered Biodistribution of Tositumomab and 131I-Tositumomab, PMID: 26338897
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab, PMID: 15613695
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma, PMID: 32800518
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study, PMID: 20458031
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement, PMID: 17325895
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas, PMID: 16186600
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma, PMID: 32243637
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911, PMID: 16896003
The radioisotope contributes significantly to the activity of radioimmunotherapy, PMID: 15585610
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes, PMID: 22955187
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-Hodgkin's lymphoma, PMID: 19707321
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy, PMID: 11884495
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, PMID: 11579112
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling, PMID: 20554734
CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma, PMID: 26832194
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma, PMID: 15084620
Cancer immunotherapy, PMID: 21355777
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma, PMID: 16110029
131I tositumomab: a viewpoint by Michael L. Grossbard, PMID: 18034571
The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab, PMID: 25383420
131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma, PMID: 19543946
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab, PMID: 16204016
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, PMID: 15731177
For research use only. Not for human or drug use.
